Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司董事会审计委员会2023年度对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee of 奥锐特药业股份有限公司 regarding the supervision of the accounting firm 天健会计师事务所 for the year 2023. It details the audit firm's qualifications, the audit procedures performed, the audit opinion issued (standard unqualified opinion), and the committee's oversight activities. The document focuses on the audit process and the committee's evaluation of the auditor's performance rather than presenting the full annual financial statements or the full annual report. It is a standalone audit-related report describing the audit firm's supervision and performance, which fits the definition of an Audit Report / Information (AR). The document length is 2182 characters, which is relatively short but contains substantive audit information, not just an announcement or certification. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). FY 2023
2024-04-28 Chinese
奥锐特药业股份有限公司2023年度独立董事述职报告（杨立荣 已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 by an independent director of a company. It details the director's duties, attendance at meetings, opinions on company matters including financial reports, internal controls, and governance issues. It is a detailed report on the independent director's activities and assessments during the year, rather than a general annual report or financial statement. This type of document is typically classified under Board/Management Information (MANG) as it relates to management and board-level disclosures about governance and director activities. The document length is under 5,000 characters but contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best fit is MANG with high confidence.
2024-04-28 Chinese
奥锐特药业股份有限公司2023年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023, including financial and non-financial internal control defects, their identification, and remediation status. The document includes detailed internal control standards, scope, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The content aligns with an Audit Report / Information filing, which covers audit reports and applied accounting principles, including internal control evaluations. The document length is 4099 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2023
2024-04-28 Chinese
奥锐特药业股份有限公司关于使用闲置自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of idle self-owned funds for entrusted financial management. It details the amount, purpose, risk control, and approval procedures related to the company's cash management activities. The document includes financial figures but does not present comprehensive financial statements or detailed financial analysis. It is a disclosure about financing activities related to cash management and investment of idle funds, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2531 characters, which is relatively short and focused on a specific financing-related announcement rather than a full report.
2024-04-28 Chinese
奥锐特药业股份有限公司2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on accounting policies. The report is unaudited as indicated. The content covers a period shorter than a full fiscal year (the first quarter of 2024). This matches the definition of an Interim / Quarterly Report (IR). The document length is over 11,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR. Q1 2024
2024-04-28 Chinese
奥锐特药业股份有限公司2023年度独立董事述职报告（陈应春）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" (2023 Annual Independent Director's Work Report) for 奥锐特药业股份有限公司. It details the independent director's background, independence, attendance at meetings, exercise of duties, communication with auditors, and evaluation of company matters during the 2023 fiscal year. The content focuses on the independent director's report on their duties and activities rather than financial results or audit opinions. It is a detailed management-related report about board activities and governance from the perspective of an independent director. This fits best under the category of Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports. The document is over 5,000 characters and contains substantive content, so it is not a mere announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.